In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex

Clinical Microbiology and Infection

Volumn 20, Issue 5, 2014, Pages

  Lavollay, M ^a,b,c,d   Dubee V ^a,b,c   Heym, B ^e,f   Herrmann, J L ^e,g   Gaillard, J L ^e,f   Gutmann, L ^a,b,c,d   Arthur, M ^a,b,c   Mainardi, J L ^a,b,c,d  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Antimicrobial susceptibility; Cefoxitin; Cystic fibrosis; Imipenem; Mycobacterium abscessus

Indexed keywords

CEFOXITIN; IMIPENEM; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CYSTIC FIBROSIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORPHOTYPE; MULTILOCUS SEQUENCE TYPING; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM MASSILIENSE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; ATYPICAL MYCOBACTERIUM; BACTERIAL COUNT; COMPLICATION; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RESPIRATORY TRACT INFECTION;

MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS;

ANTI-BACTERIAL AGENTS; CEFOXITIN; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; NONTUBERCULOUS MYCOBACTERIA; RESPIRATORY TRACT INFECTIONS;

EID: 84901622081     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12405     Document Type: Article

References (20)

1. Griffith DE. Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 810-812.
2. Roux AL, Catherinot E, Ripoll F et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47: 4124-4128.
3. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
4. Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25: 545-582.
5. Adekambi T, Reynaud-Gaubert M, Greub G et al. Amoebal coculture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42: 5493-5501.
6. Adekambi T, Berger P, Raoult D et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-143.
7. Leao SC, Tortoli E, Euzeby JP et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-2313.
8. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376.
9. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781.
10. Koh WJ, Jeon K, Lee NY et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-410.
11. Harada T, Akiyama Y, Kurashima A et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012; 50: 3556-3561.
12. Philley JV, Griffith DE. Management of nontuberculous mycobacterial (NTM) lung disease. Semin Respir Crit Care Med 2013; 34: 135-142.
13. Macheras E, Roux AL, Bastian S et al. Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol 2011; 49: 491-499.
14. Woods GL, Brown-Elliott BA, Conville PS et al. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard, M24-A2, 2nd edn. Wayne, PA: CLSI, 2011.
15. Palomino JC, Martin A, Camacho M et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 2720-2722.
16. Etienne G, Villeneuve C, Billman-Jacobe H et al. The impact of the absence of glycopeptidolipids on the ultrastructure, cell surface and cell wall properties, and phagocytosis of Mycobacterium smegmatis. Microbiology 2002; 148: 3089-3100.
17. Catherinot E, Roux AL, Macheras E et al. Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 2009; 47: 271-274.
18. Mizuguchi Y, Ogawa M, Udou T. Morphological changes induced by β-lactam antibiotics in Mycobacterium avium-intracellulare complex. Antimicrob Agents Chemother 1985; 27: 541-547.
19. Youmans AS, Youmans GP. The effect of 'Tween 80' in vitro on the bacteriostatic activity of twenty compounds for Mycobacterium tuberculosis. J Bacteriol 1948; 56: 245-252.
20. Sanders CV, Greenberg RN, Marier RL. Cefamandole and cefoxitin. Ann Intern Med 1985; 103: 70-78.